Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy

Carvedilol

“…[1][2][3]52 Most of these studies, which lasted one to six months, found either no benefit or some improvement in hemodynamic function, reduced symptoms, reduced hospitalizations, increased exercise tolerance, and an improved neurohormonal milieu. [1][2][3][44][45][46][47][48][49][50][51][52][53][54][55] Although there was no benefit in terms of survival, these studies provided evidence that b -adrenoreceptor-antagonist drugs could be administered to patients with heart failure with a reasonable degree of safety and some clinical benefit. In addition, several placebocontrolled studies suggested that b -adrenoreceptorantagonist drugs reduced mortality, especially the risk of sudden death, in patients who had survived myocardial infarction with moderately severe left ventricular dysfunction.…”

Utilización de betabloqueadores en el tratamiento de la insuficiencia cardiaca

“…Progresivamente hasta 1998 se desarrolla una intensa investigación sobre este problema pero en la que faltan ECC de gran tamaño. Hasta esa fecha, que marcamos como límite por suponer el comienzo de los ECC de gran tamaño descritos más adelante, pueden encontrarse un mínimo de 24 ECC, 4 de ellos de apreciable tamaño (23-26) y al menos 5 revisiones sistemáticas (10,(27)(28)(29)(30): Recogemos sucintamente las características y resultados de estos trabajos:…”

Cardiovascular Problems in Peritoneal Dialysis Patients: A Short Overview

“…Low-dose beta-blocking agents improve the New York Heart Association functional class and left ventricular ejection fraction in patients with idiopathic and ischemic dilated cardiomyopathy (79). No data exist concerning the efficacy of drug therapy in heart failure in dialysis patients, despite the fact that the etiology of heart failure is different from that in non renal patients.…”